Progress Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 21-01-2025
- Paid Up Capital ₹ 0.11 M
as on 21-01-2025
- Company Age 10 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.65 Cr
as on 21-01-2025
- Revenue 13943.69%
(FY 2023)
- Profit 20948.03%
(FY 2023)
- Ebitda 35715.54%
(FY 2023)
- Net Worth 14575.03%
(FY 2023)
- Total Assets 10953.38%
(FY 2023)
About Progress Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 0.11 M.
The company currently has active open charges totaling ₹2.65 Cr.
Ashutosh Pandey, Balasaheb Nikam, and Laxman Nikam serve as directors at the Company.
- CIN/LLPIN
U74999MH2014PTC257867
- Company No.
257867
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Sep 2014
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Progress Life Sciences?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashutosh Pandey  | Director | 25-Jul-2023 | Current |
| Balasaheb Nikam | Director | 08-Sep-2014 | Current |
| Laxman Nikam | Director | Current |
Financial Performance of Progress Life Sciences.
Progress Life Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 13943.69% increase. The company also saw a substantial improvement in profitability, with a 20948.03% increase in profit. The company's net worth Soared by an impressive increase of 14575.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Progress Life Sciences?
In 2023, Progress Life Sciences had a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Progress-Biosciences Private LimitedActive 3 years 5 monthsAshutosh Pandey and Balasaheb Nikam are mutual person
- Atomix Engineering Private LimitedActive 1 month 15 days
Ashutosh Pandey and Balasaheb Nikam are mutual person
Charges (Loans)
₹26.50 M
₹0
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 2.65 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Jul 2022 | Axis Bank Limited | ₹4.00 M | Open |
| 18 Feb 2022 | Axis Bank Limited | ₹2.25 Cr | Open |
How Many Employees Work at Progress Life Sciences?
Progress Life Sciences has a workforce of 16 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Progress Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Progress Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.